公开(公告)号：US10323026B2

公开(公告)日：2019-06-18

申请号：US15474192

申请日：2017-03-30

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Shuhei Ikeda ,  Hideyuki Sugiyama ,  Jumpei Aida ,  Hidekazu Tokuhara ,  Tomohiro Okawa ,  Yuya Oguro ,  Minoru Nakamura ,  Masataka Murakami

IPC: C07D413/14 ,  C07D401/08 ,  C07D405/14 ,  C07D413/08 ,  C07D401/06 ,  C07D413/06

Abstract: The present invention provides a compound having an MAGL inhibitory action, and useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

公开(公告)号：US10202376B2

公开(公告)日：2019-02-12

申请号：US15538297

申请日：2015-12-21

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Eiji Kimura ,  Yuhei Miyanohana ,  Masaki Ogino ,  Yuta Tanaka ,  Makoto Fushimi ,  Tomohiro Okawa ,  Yuki Hanya ,  Tatsuki Koike

IPC: C07D471/04 ,  A61K31/437 ,  C07D487/04 ,  A61P25/00 ,  A61P29/00

Abstract: Provided is a compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and is useful as a prophylactic or therapeutic agent for major depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, (excluding N-(4-bromo-3-(1H-1,2,4-triazol-5-yl)thiophen-2-yl)-2-(imidazo[1,2-a]pyridin-5-yl)acetamide) or a salt thereof.

公开(公告)号：US09776962B2

公开(公告)日：2017-10-03

申请号：US14898633

申请日：2014-08-08

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Jumpei Aida ,  Yayoi Yoshitomi ,  Yuko Hitomi ,  Naoyoshi Noguchi ,  Yasuhiro Hirata ,  Hideki Furukawa ,  Akito Shibuya ,  Koji Watanabe ,  Yasufumi Miyamoto ,  Tomohiro Okawa ,  Nobuyuki Takakura ,  Seiji Miwatashi

IPC: C07D211/34 ,  C07D211/22 ,  C07D213/30 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/10 ,  C07D413/14

CPC classification number: C07D211/34 ,  C07D211/22 ,  C07D213/30 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/10 ,  C07D413/14

Abstract: Provided is a novel aromatic ring compound having a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula: wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a GPR40 agonist activity and a GLP-1 secretagogue action, is useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and affords superior efficacy.

公开(公告)号：US09181186B2

公开(公告)日：2015-11-10

申请号：US14377951

申请日：2013-02-12

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Seiji Miwatashi ,  Hideo Suzuki ,  Tomohiro Okawa ,  Yasufumi Miyamoto ,  Takeshi Yamasaki ,  Yuko Hitomi ,  Yasuhiro Hirata

IPC: C07D213/64 ,  C07D405/14 ,  C07D401/12 ,  C07D239/34 ,  C07D213/30 ,  C07D213/68 ,  C07D213/69 ,  C07D213/55 ,  C07D403/12

CPC classification number: C07D213/64 ,  C07D213/30 ,  C07D213/55 ,  C07D213/68 ,  C07D213/69 ,  C07D239/34 ,  C07D401/12 ,  C07D403/12 ,  C07D405/14

Abstract: Provided is an aromatic ring compound having a GPR40 agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a GPR40 agonist activity, and is useful as an agent for the prophylaxis or treatment of diabetes and the like.

Abstract translation: 提供具有GPR40激动剂活性的芳环化合物。 由式（I）表示的化合物：其中每个符号如说明书所述，或其盐具有GPR40激动剂活性，并且可用作预防或治疗糖尿病等的药剂。